Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 88

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 88
---
 designees
have not had any material relationship with us within the past three years. WallachBeth served as: (i) the placement agent in connection
with our sale of convertible bridge notes in 2021 and 2022, (ii) the underwriter for our initial public offering that closed on September
6, 2022; (iii) the placement agent for a registered direct offering and concurrent private placement consummated in March 2024; (iv) financial
advisor and placement agent for a warrant inducement private placement and a registered direct offering and concurrent private placement,
all of which were consummated in August 2024, (v) as placement agent for a registered direct offering and concurrent private placement
consummated in October 2024, and (vi) as financial advisor for the Warrant Inducement consummated in February 2025, pursuant to which
WallachBeth received cash compensation and warrants. See the section entitled “The Private Placement” above for more information
about the compensation received in connection with the Warrant Inducement.

The table below lists the Selling Stockholders and
provides information regarding their beneficial ownership of shares of Common Stock by each of the Selling Stockholders. The second column
lists the number of shares of Common Stock beneficially owned by each of the Selling Stockholders, based on its ownership of the shares
of Common Stock, the Common Warrants and shares of Comon Stock issuable upon exercise of warrants acquired in offerings prior to the transactions
described in the section entitled, “The Private Placement,” as of April 10, 2025, assuming exercise of the Common Warrants
held by the Selling Stockholders on that date, without regard to any limitations on exercises. The third column lists the maximum number
of shares of Common Stock being offered by this prospectus by the Selling Stockholders, also without regard to any limitations on exercises.

This prospectus generally covers the resale of the
maximum number of shares of Common Stock issuable upon exercise of the Common Warrants, determined as if the outstanding Common Warrants
were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC,
each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the
registration right agreement, without regard to any limitations on the exercise of the Common Warrants. The fourth and fifth columns assume
the sale of all of the shares offered by the Selling